Search

Dextroamphetamine

Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]

Lithium citrate

Oxyphenonium

The drug has also been used in the form of eye drops for mydriatic effect. [PubChem] … A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of atropine.

CR665

In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound. … CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid receptor agonists.

Glymidine

It is used for the concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.

Iodide I-131

Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. … or image the isotope.

Telisotuzumab vedotin

[L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options. … to be approved for this specific patient population.

Gedatolisib

[L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).

Dinoprostone

As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour. … Dinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts.

Alosetron

Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. … In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use.